What is PharmaDiversion?
PharmaDiversion operates as a specialized consultancy firm dedicated to DEA compliance and diversion control. With over 36 years of operational experience, the company provides essential audits, training, and expert guidance to a diverse clientele, including pharmacies, physicians, pharmaceutical manufacturers, and specialized treatment facilities. By offering tailored compliance strategies, PharmaDiversion enables its partners to navigate complex regulatory frameworks while effectively mitigating the risks associated with drug diversion. The firm's market position is defined by its deep institutional knowledge and its ability to translate intricate federal requirements into actionable, day-to-day operational protocols for healthcare providers.
How much funding has PharmaDiversion raised?
PharmaDiversion has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in PharmaDiversion
PPP
Public-Private Partnership
What's next for PharmaDiversion?
With the infusion of this recent capital, PharmaDiversion is poised to scale its service delivery model and expand its footprint within the healthcare sector. The strategic roadmap likely involves the integration of advanced data analytics to bolster its auditing capabilities and the development of more robust, scalable training platforms. As regulatory scrutiny regarding controlled substances continues to intensify, the company is well-positioned to capture additional market share by providing the necessary infrastructure for organizations to maintain rigorous compliance standards. Future growth will likely focus on deepening its presence in the treatment facility market, where the demand for specialized diversion control expertise is at an all-time high.
See full PharmaDiversion company page
